T. Rowe Price Investment Management, Inc. Iovance Biotherapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 5,834,456 shares of IOVA stock, worth $20.7 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
5,834,456
Previous 5,861,279
0.46%
Holding current value
$20.7 Million
Previous $55 Million
21.55%
% of portfolio
0.03%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding IOVA
# of Institutions
343Shares Held
247MCall Options Held
2.51MPut Options Held
3.5M-
Vanguard Group Inc Valley Forge, PA27.5MShares$97.5 Million0.0% of portfolio
-
Mhr Fund Management LLC New York, NY24.4MShares$86.4 Million24.02% of portfolio
-
Perceptive Advisors LLC New York, NY22.1MShares$78.3 Million5.46% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$75.1 Million0.0% of portfolio
-
State Street Corp Boston, MA12.2MShares$43.4 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $559M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...